{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T15:56:12Z","timestamp":1781711772699,"version":"3.54.5"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T00:00:00Z","timestamp":1756598400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001505","name":"Health Research Council of New Zealand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.neuropharm.2025.110670","type":"journal-article","created":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T22:33:56Z","timestamp":1756593236000},"page":"110670","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Qualitative content analysis of expectations in participants with depression about to begin LSD microdosing treatment: Identifying the need for psychedelic expectancy measures"],"prefix":"10.1016","volume":"280","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-6936-4587","authenticated-orcid":false,"given":"Carina Joy","family":"Donegan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9352-2873","authenticated-orcid":false,"given":"Dimitri","family":"Daldegan-Bueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tehseen","family":"Noorani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Sumner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3283-2691","authenticated-orcid":false,"given":"Anna","family":"Forsyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8013-1208","authenticated-orcid":false,"given":"Nicholas","family":"Hoeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6311-9856","authenticated-orcid":false,"given":"Frederick","family":"Sundram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3760-7896","authenticated-orcid":false,"given":"David","family":"Menkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh","family":"Muthukumaraswamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2025.110670_bib1","series-title":"Delineating the Association Between Psychedelic Drug Use and Facets of Gratitude, Aesthetic Experience, and Relationships with Nature. Dissertation","author":"Aday","year":"2021"},{"key":"10.1016\/j.neuropharm.2025.110670_bib2","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/s00213-022-06123-7","article-title":"Great expectations: recommendations for improving the methodological rigor of psychedelic clinical trials","volume":"239","author":"Aday","year":"2022","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2025.110670_bib3","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-036169","article-title":"Development of the generic, multidimensional treatment expectation questionnaire (TEX-Q) through systematic literature review, expert surveys and qualitative interviews","volume":"10","author":"Alberts","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.neuropharm.2025.110670_bib4","article-title":"Recruitment and retention of clinical trial participants: understanding motivations of patients with chronic pain and other populations","volume":"4","author":"Anastasi","year":"2023","journal-title":"Front Pain Res (Lausanne)"},{"key":"10.1016\/j.neuropharm.2025.110670_bib5","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12954-019-0308-4","article-title":"Psychedelic microdosing benefits and challenges: an empirical codebook","volume":"16","author":"Anderson","year":"2019","journal-title":"Harm Reduct. J."},{"key":"10.1016\/j.neuropharm.2025.110670_bib6","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12954-019-0333-3","article-title":"Twenty percent better with 20 micrograms? A qualitative study of psychedelic microdosing self-rapports and discussions on YouTube","volume":"16","author":"Andersson","year":"2019","journal-title":"Harm Reduct. J."},{"key":"10.1016\/j.neuropharm.2025.110670_bib7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/YIC.0b013e328332055c","article-title":"Patient motivation for participating in clinical trials for depression: validation of the motivation for clinical trials inventory-depression","volume":"25","author":"Andresen","year":"2010","journal-title":"International clinical psychopharmacology"},{"key":"10.1016\/j.neuropharm.2025.110670_bib8","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1111\/dar.13480","article-title":"Motives for the use of serotonergic psychedelics: a systematic review","volume":"41","author":"Basedow","year":"2022","journal-title":"Drug Alcohol Rev."},{"key":"10.1016\/j.neuropharm.2025.110670_bib9","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1111\/dar.13480","article-title":"Motives for the use of serotonergic psychedelics: a systematic review","volume":"41","author":"Basedow","year":"2022","journal-title":"Drug Alcohol Rev."},{"key":"10.1016\/j.neuropharm.2025.110670_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.comppsych.2023.152431","article-title":"The influence of psychological traits and prior experience on treatment expectations","volume":"127","author":"Basedow","year":"2023","journal-title":"Compr. Psychiatry"},{"key":"10.1016\/j.neuropharm.2025.110670_bib11","article-title":"An introduction to sample selection bias in sociological data","volume":"386\u2013398","author":"Berk","year":"1983","journal-title":"Am. Sociol. Rev."},{"key":"10.1016\/j.neuropharm.2025.110670_bib12","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.biopsych.2019.05.019","article-title":"Acute subjective and behavioral effects of microdoses of Lysergic acid diethylamide in healthy human volunteers","volume":"86","author":"Bershad","year":"2019","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2025.110670_bib13","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1177\/14687941221138409","article-title":"Why do people participate in research interviews? Participant orientations and ethical contracts in interviews with victims of interpersonal violence","volume":"24","author":"Bredal","year":"2024","journal-title":"Qual. Res."},{"key":"10.1016\/j.neuropharm.2025.110670_bib14","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1177\/0272989X15579172","article-title":"Patients or volunteers? The impact of motivation for trial participation on the efficacy of patient decision aids: a secondary analysis of a cochrane systematic review","volume":"35","author":"Brown","year":"2015","journal-title":"Med. Decis. Mak."},{"key":"10.1016\/j.neuropharm.2025.110670_bib15","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1007\/s00213-022-06221-6","article-title":"Expectancy in placebo-controlled trials of psychedelics: if so, so what?","volume":"239","author":"Butler","year":"2022","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2025.110670_bib16","first-page":"1","article-title":"Psychedelic microdosing: prevalence and subjective effects","author":"Cameron","year":"2020","journal-title":"J. Psychoact. Drugs"},{"key":"10.1016\/j.neuropharm.2025.110670_bib17","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1177\/0269881118754710","article-title":"Psychedelics and the essential importance of context","volume":"32","author":"Carhart-Harris","year":"2018","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2025.110670_bib18","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.2147\/PPA.S110632","article-title":"Long-term antidepressant use: patient perspectives of benefits and adverse effects","volume":"10","author":"Cartwright","year":"2016","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.neuropharm.2025.110670_bib19","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/jclp.20754","article-title":"Expectations","volume":"67","author":"Constantino","year":"2011","journal-title":"J. Clin. Psychol."},{"key":"10.1016\/j.neuropharm.2025.110670_bib20","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1080\/10503307.2010.497508","article-title":"The relationship between therapist and client hope with therapy outcomes","volume":"20","author":"Coppock","year":"2010","journal-title":"Psychother. Res."},{"key":"10.1016\/j.neuropharm.2025.110670_bib21","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s11845-021-02668-2","article-title":"Psychedelic perceptions: mental health service user attitudes to psilocybin therapy","volume":"191","author":"Corrigan","year":"2022","journal-title":"Ir. J. Med. Sci."},{"key":"10.1016\/j.neuropharm.2025.110670_bib22","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1186\/s13063-024-08384-3","article-title":"LSDDEP2: study protocol for a randomised, double-dummy, triple-blind, active placebo-controlled, parallel groups trial of LSD microdosing in patients with major depressive disorder","volume":"25","author":"Daldegan-Bueno","year":"2024","journal-title":"Trials"},{"key":"10.1016\/j.neuropharm.2025.110670_bib23","doi-asserted-by":"crossref","DOI":"10.1111\/adb.13143","article-title":"Repeated low doses of LSD in healthy adults: a placebo-controlled, dose-response study","volume":"27","author":"de Wit","year":"2022","journal-title":"Addict. Biol."},{"key":"10.1016\/j.neuropharm.2025.110670_bib24","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0005-7916(00)00012-4","article-title":"Psychometric properties of the credibility\/expectancy questionnaire","volume":"31","author":"Devilly","year":"2000","journal-title":"J. Behav. Ther. Exp. Psychiatr."},{"key":"10.1016\/j.neuropharm.2025.110670_bib25","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s40814-023-01399-8","article-title":"An open-label pilot trial assessing tolerability and feasibility of LSD microdosing in patients with major depressive disorder (LSDDEP1)","volume":"9","author":"Donegan","year":"2023","journal-title":"Pilot Feasibility Stud"},{"key":"10.1016\/j.neuropharm.2025.110670_bib26","series-title":"The Palgrave Handbook of the Anthropology of Technology 291-308","article-title":"Set, setting, and clinical trials: colonial technologies and psychedelics: experiment","author":"Dumit","year":"2022"},{"key":"10.1016\/j.neuropharm.2025.110670_bib27","series-title":"How to Change Your Mind: Michael Pollan","author":"Ellwood","year":"2022"},{"key":"10.1016\/j.neuropharm.2025.110670_bib28","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1080\/08870446.2017.1293056","article-title":"Enhancing treatment effectiveness through social modelling: a pilot study","volume":"32","author":"Faasse","year":"2017","journal-title":"Psychol. Health"},{"key":"10.1016\/j.neuropharm.2025.110670_bib29","series-title":"The Psychedelic Explorer's Guide : Safe, Therapeutic, and Sacred Journeys","author":"Fadiman","year":"2011"},{"key":"10.1016\/j.neuropharm.2025.110670_bib30","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s00213-019-05417-7","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers","volume":"237","author":"Family","year":"2020","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2025.110670_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyg.2021.645246","article-title":"Psychedelic harm reduction and integration: a transtheoretical model for clinical practice","volume":"12","author":"Gorman","year":"2021","journal-title":"Front. Psychol."},{"key":"10.1016\/j.neuropharm.2025.110670_bib32","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.nedt.2017.06.002","article-title":"Methodological challenges in qualitative content analysis: a discussion paper","volume":"56","author":"Graneheim","year":"2017","journal-title":"Nurse Educ. Today"},{"key":"10.1016\/j.neuropharm.2025.110670_bib33","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","article-title":"Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance","volume":"187","author":"Griffiths","year":"2006","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2025.110670_bib34","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/poq\/nfh002","article-title":"The role of Topic interest in survey participation decisions","volume":"68","author":"Groves","year":"2004","journal-title":"Public Opin. Q."},{"key":"10.1016\/j.neuropharm.2025.110670_bib35","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1007\/s00586-013-2803-8","article-title":"How do low back pain patients conceptualize their expectations regarding treatment? Content analysis of interviews","volume":"22","author":"Haanstra","year":"2013","journal-title":"Eur. Spine J."},{"key":"10.1016\/j.neuropharm.2025.110670_bib36","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1177\/0269881116677852","article-title":"Set and setting, psychedelics and the placebo response: an extra-pharmacological perspective on psychopharmacology","volume":"30","author":"Hartogsohn","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2025.110670_bib37","doi-asserted-by":"crossref","DOI":"10.1177\/2050324516683325","article-title":"Constructing drug effects: a history of set and setting","volume":"3","author":"Hartogsohn","year":"2017","journal-title":"Drug Science, Policy and Law"},{"key":"10.1016\/j.neuropharm.2025.110670_bib38","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1007\/s00213-022-06249-8","article-title":"Set and setting in microdosing: an oft-overlooked principle","volume":"239","author":"Hartogsohn","year":"2022","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2025.110670_bib39","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1080\/02791072.2022.2080616","article-title":"Psychedelic microdosing, mindfulness, and anxiety: a cross-sectional mediation study","volume":"55","author":"Hartong","year":"2023","journal-title":"J. Psychoact. Drugs"},{"key":"10.1016\/j.neuropharm.2025.110670_bib40","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1093\/ijnp\/pyz029","article-title":"Motives and side-effects of microdosing with psychedelics among users","volume":"22","author":"Hutten","year":"2019","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2025.110670_bib41","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.euroneuro.2020.10.002","article-title":"Mood and cognition after administration of low LSD doses in healthy volunteers: a placebo controlled dose-effect finding study","volume":"41","author":"Hutten","year":"2020","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2025.110670_bib42","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1038\/s41598-021-81446-7","article-title":"Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing","volume":"11","author":"Kaertner","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2025.110670_bib43","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s11013-009-9141-7","article-title":"\u201cMaybe I Made Up the Whole Thing\u201d: Placebos and Patients' experiences in a randomized controlled trial","volume":"33","author":"Kaptchuk","year":"2009","journal-title":"Culture, Medicine, and Psychiatry"},{"key":"10.1016\/j.neuropharm.2025.110670_bib44","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1371\/journal.pmed.0050045","article-title":"Initial severity and antidepressant benefits: a meta-analysis of data submitted to the food and drug administration","volume":"5","author":"Kirsch","year":"2008","journal-title":"PLoS Med."},{"key":"10.1016\/j.neuropharm.2025.110670_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.actpsy.2024.104194","article-title":"The impact of hope levels on treatment adherence in psychiatric patients","volume":"244","author":"K\u0131sao\u011flu","year":"2024","journal-title":"Acta Psychol."},{"key":"10.1016\/j.neuropharm.2025.110670_bib46","series-title":"How Silicon Valley Rediscovered LSD","author":"Kulcher","year":"2017"},{"key":"10.1016\/j.neuropharm.2025.110670_bib47","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3389\/fpsyg.2017.00233","article-title":"Patients' expectations regarding medical treatment: a critical review of concepts and their assessment","volume":"8","author":"Laferton","year":"2017","journal-title":"Front. Psychol."},{"key":"10.1016\/j.neuropharm.2025.110670_bib48","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1741-7015-6-7","article-title":"More in hope than expectation: a systematic review of women's expectations and experience of pain relief in labour","volume":"6","author":"Lally","year":"2008","journal-title":"BMC Med."},{"key":"10.1016\/j.neuropharm.2025.110670_bib49","article-title":"Psychedelic microdosing: a subreddit analysis","volume":"1\u201312","author":"Lea","year":"2019","journal-title":"J. Psychoact. Drugs"},{"key":"10.1016\/j.neuropharm.2025.110670_bib50","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1007\/s00213-020-05477-0","article-title":"Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders","volume":"237","author":"Lea","year":"2020","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2025.110670_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2019.11.008","article-title":"Microdosing psychedelics: motivations, subjective effects and harm reduction","volume":"75","author":"Lea","year":"2020","journal-title":"Int J Drug Policy"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110670_bib52","doi-asserted-by":"crossref","DOI":"10.2307\/2060063","article-title":"A theory of migration","volume":"3","author":"Lee","year":"1966","journal-title":"Demography"},{"key":"10.1016\/j.neuropharm.2025.110670_bib53","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1369-7625.2009.00570.x","article-title":"Why health expectations and hopes are different: the development of a conceptual model","volume":"12","author":"Leung","year":"2009","journal-title":"Health Expect."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110670_bib54","doi-asserted-by":"crossref","DOI":"10.1111\/anoc.12226","article-title":"\u2018psychedelics are no magic pill\u2019: the narrative and embodied dimensions of psychedelic integration in Denmark","volume":"36","author":"Marie","year":"2024","journal-title":"Anthropol. Conscious."},{"key":"10.1016\/j.neuropharm.2025.110670_bib55","series-title":"Qualitative Content Analysis : a step-by-step Guide","author":"Mayring","year":"2021"},{"issue":"3\/4","key":"10.1016\/j.neuropharm.2025.110670_bib56","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1108\/DHS-03-2024-0013","article-title":"The psychedelic mind: current user perceptions of psychedelic drugs and their use","volume":"25","author":"McGruddy","year":"2024","journal-title":"Drugs Habit Soc. Policy"},{"key":"10.1016\/j.neuropharm.2025.110670_bib57","article-title":"Exploring motivations, experiences, and consequences of psychedelic use in aotearoa New Zealand","volume":"1\u201312","author":"Mills","year":"2025","journal-title":"J Psychoactive Drugs"},{"key":"10.1016\/j.neuropharm.2025.110670_bib58","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/s41386-023-01772-4","article-title":"Greater subjective effects of a low dose of LSD in participants with depressed mood","volume":"49","author":"Molla","year":"2024","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2025.110670_bib59","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/jamapsychiatry.2025.0044","article-title":"Safety and efficacy of repeated low-dose LSD for ADHD treatment in adults: a randomized clinical trial","volume":"82","author":"Mueller","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.neuropharm.2025.110670_bib60","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.biopsych.2023.03.013","article-title":"Acute mood-elevating properties of microdosed Lysergic acid diethylamide in healthy volunteers: a home-administered randomized controlled trial","volume":"94","author":"Murphy","year":"2023","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2025.110670_bib61","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.biopsych.2023.03.013","article-title":"Acute mood-elevating properties of microdosed Lysergic acid diethylamide in healthy volunteers: a home-administered randomized controlled trial","volume":"94","author":"Murphy","year":"2023","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2025.110670_bib62","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1080\/17512433.2021.1933434","article-title":"Blinding and expectancy confounds in psychedelic randomized controlled trials","volume":"14","author":"Muthukumaraswamy","year":"2021","journal-title":"Expet Rev. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110670_bib63","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1080\/17512433.2021.1933434","article-title":"Blinding and expectancy confounds in psychedelic randomized controlled trials","volume":"14","author":"Muthukumaraswamy","year":"2021","journal-title":"Expet Rev. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110670_bib64","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1556\/2054.2019.018","article-title":"Making psychedelics into medicines: the politics and paradoxes of medicalization","volume":"4","author":"Noorani","year":"2020","journal-title":"Journal of Psychedelic Studies"},{"key":"10.1016\/j.neuropharm.2025.110670_bib65","article-title":"The Pollan effect: psychedelic research between world and word","author":"Noorani","year":"2020","journal-title":"Fieldsights"},{"key":"10.1016\/j.neuropharm.2025.110670_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.727050","article-title":"New frontiers or a bursting bubble? Psychedelic therapy beyond the dichotomy","volume":"12","author":"Noorani","year":"2021","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.neuropharm.2025.110670_bib67","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.1017\/S0033291723001289","article-title":"Dark loops: contagion effects, consistency and chemosocial matrices in psychedelic-assisted therapy trials","volume":"53","author":"Noorani","year":"2023","journal-title":"Psychol. Med."},{"key":"10.1016\/j.neuropharm.2025.110670_bib68","series-title":"Defensive Pessimism, Optimism, and Pessimism","author":"Norem","year":"2001"},{"key":"10.1016\/j.neuropharm.2025.110670_bib69","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1037\/0022-3514.51.6.1208","article-title":"Defensive pessimism: harnessing anxiety as motivation","volume":"51","author":"Norem","year":"1986","journal-title":"Journal of personality and social psychology"},{"key":"10.1016\/j.neuropharm.2025.110670_bib70","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1186\/s13063-020-04857-3","article-title":"Parents' understanding and motivation to take part in a randomized controlled trial in the field of adolescent mental health: a qualitative study","volume":"21","author":"O'Keeffe","year":"2020","journal-title":"Trials"},{"key":"10.1016\/j.neuropharm.2025.110670_bib71","series-title":"Proceedings of the CHI Conference on Human Factors in Computing Systems","first-page":"1","article-title":"Quantifying the pollan effect: investigating the impact of emerging psychiatric interventions on online mental health discourse","author":"Pendse","year":"2024"},{"key":"10.1016\/j.neuropharm.2025.110670_bib72","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0211023","article-title":"A systematic study of microdosing psychedelics","volume":"14","author":"Polito","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2025.110670_bib73","series-title":"How to Change your Mind the New Science of Psychedelics","author":"Pollan","year":"2019"},{"key":"10.1016\/j.neuropharm.2025.110670_bib74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jad.2009.01.029","article-title":"Meta-analysis of the placebo response in antidepressant trials","volume":"118","author":"Rief","year":"2009","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.neuropharm.2025.110670_bib75","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3389\/fphar.2017.00974","article-title":"Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression","volume":"8","author":"Roseman","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110670_bib76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/157340010790596571","article-title":"Expectancy and the treatment of depression: a review of experimental methodology and effects on patient outcome","volume":"6","author":"Rutherford","year":"2010","journal-title":"Curr. Psychiatry Rev."},{"key":"10.1016\/j.neuropharm.2025.110670_bib77","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1176\/appi.ajp.2016.16020225","article-title":"Patient expectancy as a mediator of placebo effects in antidepressant clinical trials","volume":"174","author":"Rutherford","year":"2017","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2025.110670_bib78","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1017\/S1478951523001475","article-title":"Disruption as an opportunity or threat: a qualitative analysis of factors influencing the attitudes of experts in serious illness care toward psychedelic-assisted therapies","volume":"21","author":"Sholevar","year":"2023","journal-title":"Palliat. Support Care"},{"key":"10.1016\/j.neuropharm.2025.110670_bib79","first-page":"3","article-title":"Consumer decision factors for initial and long-term use of complementary and alternative medicine","volume":"13","author":"Sirois","year":"2008","journal-title":"Compl. Health Pract. Rev."},{"key":"10.1016\/j.neuropharm.2025.110670_bib80","series-title":"WIRED","article-title":"Under pressure, Silicon Valley workers turn to LSD microdosing","author":"Solon","year":"2016"},{"key":"10.1016\/j.neuropharm.2025.110670_bib81","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s44184-023-00044-9","article-title":"Managing expectations with psychedelic microdosing","volume":"2","author":"Syed","year":"2023","journal-title":"npj Mental Health Research"},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110670_bib82","first-page":"512","article-title":"Expectancy effects in psychedelic trials","volume":"9","author":"Szigeti","year":"2024","journal-title":"Biol. Psychiatry Cogn. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110670_bib83","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s10591-012-9201-y","article-title":"A literature review of therapeutic expectancy effects","volume":"34","author":"Tambling","year":"2012","journal-title":"Contemp. Fam. Ther."},{"key":"10.1016\/j.neuropharm.2025.110670_bib84","doi-asserted-by":"crossref","DOI":"10.1111\/hex.13951","article-title":"Does outcome expectancy predict outcomes in online depression prevention? Secondary analysis of randomised-controlled trials","volume":"27","author":"Thielecke","year":"2024","journal-title":"Health Expect."},{"key":"10.1016\/j.neuropharm.2025.110670_bib85","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s11920-007-0061-3","article-title":"The STAR\u2217D Project results: a comprehensive review of findings","volume":"9","author":"Warden","year":"2007","journal-title":"Curr. Psychiatry Rep."},{"key":"10.1016\/j.neuropharm.2025.110670_bib86","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s12906-019-2584-7","article-title":"What motivates new, established and long-term users of herbal medicine: is there more than push and pull?","volume":"19","author":"Welz","year":"2019","journal-title":"BMC Compl. Alternative Med."},{"key":"10.1016\/j.neuropharm.2025.110670_bib87","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1021\/acsptsci.0c00194","article-title":"The subjective effects of psychedelics are necessary for their enduring therapeutic effects","volume":"4","author":"Yaden","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.neuropharm.2025.110670_bib88","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jamapsychiatry.2020.3672","article-title":"Psychedelics in Psychiatry\u2014Keeping the Renaissance from going off the rails","volume":"78","author":"Yaden","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.neuropharm.2025.110670_bib89","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1177\/1740774512465064","article-title":"Development of the Stanford Expectations of Treatment Scale (SETS): a tool for measuring patient outcome expectancy in clinical trials","volume":"9","author":"Younger","year":"2012","journal-title":"Clin. Trials"},{"issue":"14","key":"10.1016\/j.neuropharm.2025.110670_bib90","doi-asserted-by":"crossref","DOI":"10.1017\/S0033291718003343","article-title":"Optimizing patient expectancy in the pharmacologic treatment of major depressive disorder","volume":"49","author":"Zilcha-Mano","year":"2019","journal-title":"Psychol. Med."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825003788?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825003788?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T21:21:18Z","timestamp":1768512078000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390825003788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":90,"alternative-id":["S0028390825003788"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110670","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Qualitative content analysis of expectations in participants with depression about to begin LSD microdosing treatment: Identifying the need for psychedelic expectancy measures","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110670","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"110670"}}